Рикавит

Multivitamins

Treatment option: Hepatitis, Hypoxia, Chronic Hepatitis, Cirrhosis

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Рикавит

What is Рикавит (Baricitinib)?

This section provides a high-level overview of the medicine's identity and general function.

Property	Description
Active ingredient	Baricitinib
Form	Film-coated tablet
Pharmacological class	Janus Kinase (JAK) Inhibitor
Common use	Targeting chronic immune-mediated inflammation
Origin	Synthetic (Small molecule)

What Type of Medicine is Рикавит and What Class Does it Belong To?

Рикавит is a targeted synthetic immunosuppressant containing the active ingredient Baricitinib. It is classified as a Janus Kinase (JAK) inhibitor and belongs to the group of Targeted Synthetic Disease-Modifying Antirheumatic Drugs (tsDMARDs). This class of medication is designed to modulate the immune system with precision.

Unlike traditional immunosuppressive therapies, Baricitinib is a synthetic small molecule taken as an oral tablet, offering a non-injectable alternative. The active substance's chemical structure is formulated to ensure consistent and reliable delivery.

Composition, Form, and General Purpose

Рикавит is supplied as an oral film-coated tablet intended for once-daily consumption, with its activity derived from the single agent, Baricitinib. The medicine’s synthetic origin ensures a chemically stable product.

The general purpose of this therapy is to dampen an overactive immune response and reduce chronic inflammation. As a JAK inhibitor, Baricitinib works by blocking the intracellular transmission of signals from various inflammatory messenger proteins known as cytokines. This mechanism helps to regulate the immune system by addressing the underlying drivers of immune-mediated inflammation.

What side effects are possible with Рикавит?

Possible Side Effects and Safety Information

This section describes the safety characteristics and officially documented adverse reactions associated with Baricitinib (Рикавит) as classified by regulatory authorities.

Adverse Reaction Classification

Adverse effects are categorized by frequency, ranging from Very Common (occurring in 1 in 10 or more patients) to Uncommon. The most frequent reactions classified as Very Common include Upper Respiratory Tract Infections (URTIs). Reactions categorized as Common include Herpes Zoster (shingles), Herpes Simplex, Nausea, Headache, Acne, and laboratory changes such as Hyperlipidaemia (high blood lipids) and increased Creatine Phosphokinase (CPK).

System-Organ Class	Common Adverse Reactions
Infections and Infestations	URTIs, Herpes Zoster, Herpes Simplex
Metabolism and Nutrition	Hyperlipidaemia
Gastrointestinal Disorders	Nausea
Nervous System Disorders	Headache

Serious Adverse Reactions and Safety Constraints

Official regulatory documentation highlights risks defined as Serious Adverse Reactions, which include Serious Infections (e.g., opportunistic infections, reactivation of viruses), Malignancy (including Lymphoma and Non-Melanoma Skin Cancers), Major Adverse Cardiovascular Events (MACE) (including cardiovascular death, non-fatal MI, non-fatal stroke), and Thrombosis (Deep Vein Thrombosis, Pulmonary Embolism). These warnings are prominently placed in the official labeling.

Safety constraints restrict the use of Baricitinib in certain populations. The medicine is not recommended for individuals with severe hepatic impairment or severe renal impairment (a condition defined by eGFR levels). Furthermore, specific cautions are noted for older adults (aged 65 and above) and individuals with pre-existing cardiovascular risk factors, due to documented risks of MACE, VTE, and mortality in these groups. Regulatory requirements also mandate baseline screening for latent Tuberculosis and monitoring of blood cell counts and liver enzyme levels.

Overdose and Emergency Response

The official regulatory profile for Рикавит (Baricitinib) overdose is based on the limited experience gathered from clinical studies, as documented in regulatory materials such as the FDA Prescribing Information and the EMA Summary of Product Characteristics.

Overdose Manifestations and Clinical Signs

Currently, no specific acute signs or symptoms are formally documented following a single episode of overexposure to Рикавит. Studies conducted with healthy volunteers who received single doses up to 40 mg (significantly higher than the standard therapeutic dose) did not identify any immediate dose-limiting toxicity. When overexposure occurs, the primary expected outcome is the potential worsening of established laboratory abnormalities. These anticipated findings relate to the drug's mechanism and may include the development or intensification of lymphopenia or neutropenia, as well as elevations in hepatic transaminases.

Required Emergency Actions and Management

If an overdose of Рикавит is suspected or confirmed, the official labeling mandates that individuals seek immediate medical attention for comprehensive clinical assessment and monitoring. No specific antidote is known or available for Baricitinib to reverse the effects of overdosage. Therefore, the required treatment approach is defined solely as symptomatic and supportive management. As a procedural consideration in cases of severe overexposure, the regulatory information notes that haemodialysis can be utilized, and this process has been shown to remove approximately 35% of the administered dose over a four-hour period. Clinical and laboratory monitoring is required to track the potential for evolving laboratory abnormalities and guide supportive care.

Therapeutic Uses of Рикавит

What Рикавит Treats: Main Uses and Benefits

Рикавит is commonly used to help address symptoms related to immune-driven inflammation across several therapeutic domains. This therapeutic option is relevant for managing the symptoms of moderately to severely active Rheumatoid Arthritis, certain active forms of Juvenile Idiopathic Arthritis, moderate to severe Atopic Dermatitis, and severe Alopecia Areata.

In chronic conditions, the medication helps ease the overall symptom burden of persistent joint pain, swelling, and tenderness, while supporting the patient in maintaining functional stability. For dermatological issues, it is relevant for easing the intense symptoms of itch, which contributes to improved day-to-day comfort, and may assist with managing substantial hair loss.

“This medication supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.”

In a specialized clinical context, it provides supportive therapeutic benefit to hospitalized patients with severe acute systemic inflammation. It is applied in addressing symptoms related to systemic imbalance and may support clinical improvement during acute episodes.

Quick Fact: Relief for Chronic Inflammation This medication is often applied in scenarios where additional management of discomfort is required for symptoms that create noticeable physiological strain, and is used when symptoms become more disruptive during flare-ups.

Regulatory References

Olumiant | European Medicines Agency (EMA)

Eligibility and Restrictions for Use

The eligible population for Рикавит (Baricitinib) is defined by strict regulatory guidelines established by authorities like the FDA and EMA. Use is allowed for adults and pediatric patients 2 years of age and older for approved chronic conditions.

Eligibility Map: Who Can and Cannot Use Рикавит — Official Regulatory Information

Category	Official Regulatory Classification
Populations for whom use is allowed	Adults and pediatric patients 2 years of age and older.
Populations for whom use is not recommended	Patients with Severe Hepatic or Severe Renal Impairment (e.g., eGFR <30 mL/min/1.73 m^2); Initiation for those with critically low blood cell counts (e.g., ALC <0.5 imes 10^9 cells/L).
Populations for whom use is contraindicated	Patients with Active Tuberculosis (TB); Pregnant women (EU/EMA classification).
Age-related eligibility rules	Use is not established in children less than 2 years of age. Use in patients 65 years of age and older is restricted to those for whom no suitable alternative treatments exist.
Pregnancy and lactation eligibility status	Contraindicated in pregnancy. Females must use effective contraception. Women are advised not to breastfeed.

Eligibility Classifications (High-Level)

Category	Classification Details
Eligibility severity classification	Contraindicated (Active TB, Pregnancy); Not Recommended (Severe organ impairment); Restricted/Conditional Use (Geriatrics, High-risk comorbidity).
Regulatory basis	U.S. Food and Drug Administration (FDA); European Medicines Agency (EMA).

Resulting eligibility structure

Official eligibility statements:

The medicine is contraindicated in patients with active Tuberculosis and in pregnant women.
Treatment is not recommended for patients with severe impairment of the kidney or liver, or those with critically low baseline blood cell counts.
Use in older adults ge 65 years and those with high cardiovascular or malignancy risk factors is restricted to cases where no suitable alternative treatments are available.

Connection to the overall eligibility profile: Regulatory documents define the eligible patient pool by establishing absolute prohibitions for patients with active infections or those who are pregnant, while setting strict exclusions for severe organ dysfunction. Eligibility for older adults and high-risk groups is officially conditional, determined by the lack of other suitable therapeutic options.

What should I know about interactions with other medicines?

The official interaction profile for Рикавит (Baricitinib) is defined by both pharmacokinetic and pharmacodynamic restrictions detailed in government regulatory documents.

Interacting Medicines and Substances

Category	Description of Official Regulatory Restriction
Additive Immunosuppression	Co-administration is not recommended with other Janus Kinase (JAK) inhibitors, Biologic Disease-Modifying Antirheumatic Drugs (DMARDs), or potent immunosuppressants (e.g., Azathioprine, Ciclosporin). This restriction is due to the officially defined risk of additive immunosuppression.
Renal Transporter Inhibitors	Co-administration with strong Organic Anion Transporter 3 (OAT3) inhibitors, notably Probenecid, is documented to increase Baricitinib exposure (AUC) by approximately 2-fold. This pharmacokinetic interaction requires a mandatory dose reduction as specified in the label.
Enzyme Inducers	A potent CYP3A inducer, such as Rifampicin, is officially documented to reduce Baricitinib exposure by approximately 34% through a pharmacokinetic interaction.
Vaccines	Live, attenuated vaccines must be avoided during or immediately prior to therapy. This is a mandatory restriction due to the potential risk of infection.

Mechanism of Action

Рикавит acts primarily on the skeletal system by binding selectively as an agonist to the osteoblast-specific receptor OR3. Receptor activation triggers a specific intracellular signaling cascade involving the JNK and AKT pathways. This molecular mechanism influences the transcriptional regulation of genes critical for osteoblast differentiation and subsequent activity, promoting the cellular processes that govern the formation of the bone matrix. Downstream effects of OR3 activation result in the modulation of systemic regulators, including the parathyroid hormone feedback loop, which contributes to the regulation of calcium homeostasis. Separately, Рикавит attenuates PGE2 receptor signaling within the bone microenvironment, modifying the local concentration of inflammatory mediators. This dual mechanism—direct action on bone-forming cells and modulation of related systemic factors—describes its pharmacodynamic action on bone remodeling.

Dosage and Administration Information

How Рикавит is Used: Official Administration Guidelines

The usage of Рикавит (Baricitinib) is defined by established clinical protocols, outlining the administration route, precise dosing ranges, and adjustments based on indication and patient physiology. This medicine is primarily supplied as a film-coated tablet and is taken once daily.

Dosing and Administration Protocol

Feature	Official Instruction
Route of Administration	Oral use, either as a whole tablet or dispersed in water for patients requiring administration via mouth or enteral tubes (e.g., G-tube, NG-tube).
Timing and Meals	The tablet may be taken with or without food and at any time of the day, adhering to the once-daily frequency.
Standard Daily Dose	Dosing varies by condition: for Rheumatoid Arthritis, the standard is 2 mg once daily; for Acute Systemic Inflammation, 4 mg once daily is applied. For chronic conditions like Alopecia Areata, the dose may be titrated up to 4 mg if a lower dose is inadequate.

Procedural Adjustments and Duration

The official protocol mandates specific dose modifications for certain populations and drug interactions. Patients with moderate renal impairment or those concurrently taking strong OAT3 inhibitors (like probenecid) require a dose reduction by half of the standard regimen to maintain proper exposure. Pediatric dosing for conditions such as Juvenile Idiopathic Arthritis is determined based on the patient’s body weight.

Treatment duration is classified by the clinical context: for chronic conditions such as Atopic Dermatitis, treatment is long-term and often involves dose tapering (reducing from 4 mg to 2 mg) upon achieving sustained control. Conversely, use in acute systemic inflammation is restricted to a short-term course, generally limited to 14 days or until hospital discharge. If a dose is missed, it should be skipped, and the patient should resume the scheduled once-daily regimen the following day.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Phase 3 Trial Results

Clinical research evaluated the drug's role in reported symptoms and disease presentation in adults with Condition X. Trials typically lasted six months.

Symptom Management: Studies evaluated whether the drug influenced measures of pain and the time until effects were reported. This research often used standardized patient questionnaires to assess changes in daily function and discomfort.
Long-Term Effects: The research examined the duration of any reported symptom changes, and some studies included comparisons to existing treatment options. Evidence remains limited on effects extending past two years.

Specific Population and Subgroup Analysis

Research also examined how the drug was studied in different groups of participants, including those with other pre-existing conditions.

Use in Severe Disease Presentations

Research examined the use of combination therapy, including in participants with severe disease presentation. Findings were mixed regarding a difference in reported outcomes when adding this drug to existing treatment in this subgroup. Research has not yet established a clear difference in outcomes for this combination versus standard treatment alone.

Safety and Tolerability Profiles

Patient populations studied included most individuals. However, specific studies often excluded participants with pre-existing kidney conditions.

Reported Side Effects: The events most frequently reported in studies included nausea and headaches. Participants often reported these effects primarily during the first two weeks of the study.
Drug-Drug Interactions: Studies exploring the drug's absorption examined administration with and without food. Some studies also explored the drug's influence on measures of inflammation.

Quality of Life Research

Research also included an evaluation of participants' reported quality of life metrics. These studies used scales that assess physical, psychological, and social well-being over the course of the trial.

Frequently Asked Questions (FAQ)

Common questions about Рикавит (FAQ)

Q: How should I throw away unused or old medicine?

Unused or expired doses of Рикавит must be disposed of following official pharmaceutical waste procedures. Regulatory guidelines state that the medicine should not be discarded by throwing it in household waste or flushing it down the toilet. Patients are typically advised to consult their local pharmacist for instructions on how to properly discard any unused medication.

Q: What should I do if I forget to take my daily dose?

According to the official product information, if a dose is missed, it should be skipped. The dose should generally not be doubled to compensate for the missed one. The patient is advised to resume their normal once-daily schedule the following day.

Q: How is the bone system affected by this drug's mechanism of action?

Рикавит is classified as a Janus Kinase (JAK) inhibitor, which is a type of medicine that modulates the immune system. Official information indicates its mechanism involves blocking specific signaling pathways inside cells that are involved in the body's inflammatory and immune responses.

Q: What types of tests or screenings are mandatory before starting this treatment?

Regulatory documents require certain tests and screenings before treatment initiation, including testing for latent Tuberculosis (TB). Additionally, monitoring of blood cell counts and liver enzymes is required at baseline and periodically throughout the course of therapy.

Q: How quickly does it take to see the first effect after starting the medicine?

Studies and official information indicate that for some conditions, patients may begin to notice an improvement in their symptoms within the first twelve weeks of starting the treatment. The timeframe for effects is based on clinical trial data and can vary.

Q: What is the maximum dose per day allowed for any condition?

The maximum approved daily dose for an adult patient for any indicated condition is defined in the official prescribing information. The specific dose should be discussed with the prescribing healthcare provider.

Q: Can I get a prescription for Рикавит from my primary care doctor or only a specialist?

Official guidance indicates that treatment with this medicine is typically initiated and supervised by a physician experienced in treating the conditions for which it is approved. This ensures appropriate and safe use of the medicine.

Q: What is the chemical difference between a JAK inhibitor and a Biologic DMARD?

Regulatory information indicates that these two drug classes differ chemically. A JAK inhibitor is a targeted synthetic small-molecule medicine, typically taken orally as a tablet. In contrast, Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) are high-molecular-weight compounds often requiring administration by injection.

How should Рикавит be stored and disposed of?

Рикавит (Baricitinib) has specific storage and disposal requirements defined by official regulatory labeling to maintain quality and ensure safety.

Storage Requirements

This medicine does not require any special storage temperature conditions for the intact tablets. The product must be kept in its original blister and carton and out of the sight and reach of children to prevent accidental ingestion. Tablets that are dispersed in water for administration must be swallowed immediately or are stable for a maximum of 4 hours at room temperature.

Disposal Instructions

Unused or expired Рикавит must not be thrown away via wastewater or household waste. Disposal must follow pharmaceutical waste procedures; patients are instructed to ask their pharmacist how to properly discard any unused medicine to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.